Trial Profile
A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Copper-gluconate/disulfiram (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Sep 2023 Status changed from completed to discontinued.
- 14 Jul 2021 Status changed from recruiting to completed.
- 06 Dec 2019 Status changed from not yet recruiting to recruiting.